Biolinq's Needle-Free Glucose Monitor, Biolinq Shine, Gains FDA Approval

Biolinq received FDA approval on October 1, 2025, for its needle-free continuous glucose monitor (CGM), the Biolinq Shine, representing a significant advancement in glucose monitoring technology. Unlike traditional CGMs, which rely on needle-based sensor insertion beneath the skin, the Biolinq Shine utilizes a microneedle array. Biolinq asserts that these microneedles are positioned up to 20 times more superficially than conventional sensors, a design intended to enhance user comfort. The Biolinq Shine is a coin-sized, patch-like device worn on the forearm, providing a less invasive and more comfortable glucose monitoring experience.